Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile
Bronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited.
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin
Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?
COPD is characterised by tissue destruction and inflammation.
Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: A phase I pilot study
COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant.
Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema
We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route.
Combined Bone Marrow‐Derived Mesenchymal Stromal Cell Therapy and One‐Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial
One‐way endobronchial valves (EBV) insertion to reduce pulmonary air trapping has been used as therapy for chronic obstructive pulmonary disease (COPD) patients.
Autologous Stromal Vascular Fraction in the Intravenous Treatment of End-Stage Chronic Obstructive Pulmonary Disease: A Phase I Trial of Safety and Tolerability
Chronic obstructive pulmonary disease (COPD) is a consistently progressive, ultimately fatal disease for which no treat- ment exists capable of either reversing or even interrupting its course.
A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema
Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema.
Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition
Ageing is characterised by an increase in the concentration of inflammatory markers in the bloodstream, a phenomenon that has been termed “inflammageing”. The inflammatory response is beneficial as an acute, transient reaction to harmful conditions, facilitating the defence, repair, turnover and adaptation of many tissues. However, chronic and low grade inflammation is likely to be detrimental for many tissues and for normal functions.
Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease
The increasingly high rates of morbidity and mortality due to acute and chronic lung diseases have emerged as one of the major public health issues globally.
Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases
It is currently thought that extracellular vesicles (EVs), such as exosomes and microvesicles, play an important autocrine/paracrine role in intercellular communication.
Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report
Idiopathic pulmonary fibrosis (IPF) is a degenerative disease characterized by fibrosis.
Mesenchymal Stem Cells in Fibrotic Disease
Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation.
Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination
Although the clinical application of new drugs has been shown to be effective in slowing disease progression and improving the quality of life in patients with pulmonary fibrosis, the damaged lung tissue does not recover with these drugs.
Clinical applications of mesenchymal stem cells in chronic lung diseases
Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair in vivo.
Mesenchymal stem cells in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a major cause of respiratory failure in critically ill patients and common outcome of various lung interstitial diseases.
Cell Therapy in Idiopathic Pulmonary Fibrosis
diopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options.
Human Mesenchymal Stem Cell Secretome from Bone Marrow or Adipose-Derived Tissue Sources for Treatment of Hypoxia-Induced Pulmonary Epithelial Injury
Alveolar epithelial dysfunction induced by hypoxic stress plays a significant role in the pathological process of lung ischemia-reperfusion injury (IRI).
Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats
Silicosis has been topping the list of high-incidence occupational diseases in developing countries and cannot be completely cured.